ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

403

Participants

Timeline

Start Date

April 7, 2017

Primary Completion Date

October 28, 2022

Study Completion Date

November 17, 2022

Conditions
Treatment Resistant DepressionElectroconvulsive TherapyECTKetaminePsychiatric DisorderDepressionMajor Depressive DisorderMajor Depressive EpisodeUnipolar Depression
Interventions
PROCEDURE

electroconvulsive therapy (ECT)

ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.

DRUG

Ketamine

Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.

Trial Locations (5)

10029

Mount Sinai, New York

21205

Johns Hopkins University School of Medicine, Baltimore

44195

Cleveland Clinic, Cleveland

77030

Baylor College of Medicine, Houston

06510

Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Bo Hu

OTHER

NCT03113968 - ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) | Biotech Hunter | Biotech Hunter